

NantHealth to Present and Exhibit on the Convergence of Precision Medicine and Value-Based Care at America's Health Insurance Plans (AHIP) Institute & Expo 2018

June 20, 2018

CULVER CITY, Calif. & SAN DIEGO--(BUSINESS WIRE)-- [NantHealth](#) (NASDAQ: NH), a next-generation healthcare company, will exhibit and present at America's Health Insurance Plans (AHIP) Institute & Expo 2018 taking place June 20-22, 2018 at the San Diego Convention Center in San Diego, CA at booth #824.

NantHealth, a Silver-Sponsor at the AHIP Institute & Expo 2018, will showcase its health IT and precision medicine solutions, including NaviNet[®], Eviti[®], GPS Cancer, and Liquid GPS[®] at booth #824.

NantHealth will present "Demystifying the Convergence of Precision Medicine and Value-Based Care" at a Breakfast Briefing in Room 33AB on Thursday, June 21, 2018 at 7:15 AM Pacific Time. Presenters Dr. Sandeep "Bobby" Reddy, Chief Medical Officer, and Kristin Lee, VP of Payer Sales and Client Engagement, will highlight the challenges and opportunities posed by precision medicine and value-based care and how health plans can navigate their convergence.

NantHealth representatives will also exhibit NaviNet, Eviti, GPS Cancer, and Liquid GPS.

- NaviNet Open[®] is a secure, multi-payer platform that lets health plans and providers exchange vital administrative and clinical information in real-time, improving communications between health plans and their provider networks.
- Eviti[®] Connect streamlines the pre-authorization of cancer treatment through the online entry of treatment plans, eliminating phone calls to health plans, while reducing denials and appeals.
- GPS Cancer[®] is a precise and comprehensive tissue-based molecular profile that integrates tumor-normal sequencing of DNA with RNA sequencing, providing oncologists with insights they can rely on to inform personalized treatment strategies.
- Liquid GPS[™] is a blood-based molecular test that provides oncologists with a powerful tool for noninvasive tumor profiling and quantitative monitoring of treatment response. Liquid GPS looks beyond cfDNA to cfrRNA, which allows profiling and trending of actionable biomarkers that cannot be assessed through cfDNA alone.

"NantHealth is thrilled to showcase its health IT and precision medicine solutions at AHIP 2018," said Dr. Bobby Reddy, CMO of NantHealth. "I am personally excited to discuss NantHealth's perspective regarding the intrinsic link between precision medicine and value-based care and how health plans can navigate their convergence." **Attend our Breakfast Briefing in Room 33AB and visit NantHealth in the Exhibit Hall at booth #824 to view NaviNet, Eviti, and GPS demos.**

About NantHealth, Inc.

NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth's focused portfolio exemplifies its unique systems-based approach to personalized healthcare and integrates novel diagnostics with large-scale, biometric and phenotypic data to track patient outcomes and deliver precision medicine. For more information, please visit www.nanthealth.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20180619006502/en/): <https://www.businesswire.com/news/home/20180619006502/en/>

NantWorks
Jen Hodson
jhodson@nantworks.com

Source: NantHealth